ClinicalTrials.gg
TerminatedNCT04854096Updated May 23, 2025Results posted

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

A Phase 2 interventional study of NS-018 and Best Available Therapy in Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by NS Pharma, Inc.. Terminated at 52 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was stopped due to a business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Primary Myelofibrosis with a site in Italy — 24 open to participants now, 43 under way, 11 of them phase 3. Primary Myelofibrosis · Italy.

Enrollment
81st of 83
7 · median 121
Started
2023
with 4 others
Phase 2
27 of 101
4 open now
Registered
71st of 101
by date

Among the 101 studies in Primary Myelofibrosis with a site in Italy, this one is the 81st largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2023, is one of 27 in phase 2, and was the 71st registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

24 of the 101 studies in Primary Myelofibrosis with a site in Italy are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Primary Myelofibrosis with a site in Italy, or all of them as a file.
02

Study summary

This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).

Read the detailed description

NS-018 will be self-administered orally at a dose of 300 mg BID. The BAT will be administered according to manufacturer's instructions and Investigator discretion. Subjects will complete study visits at Screening, Day 1 and Day 15 of Cycle 1, 2, 3, 4, 5, 6 and Day 1 of every cycle thereafter. At these visits, blood/urine sampling, spleen measurements, bone marrow assessments, patient-reported outcome (PRO) assessments, and safety assessments may be performed.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary MF, post-PVMF or post-ETMF according to the DIPSS risk categories of intermediate-2 or high-risk MF
  • Average count of \<50,000/µL at Screening based on 2 measurements taken on different days; both measurements must be \<50,000/µL.
  • performance status ≤2.
  • >6 months.
  • Spleen volume of at least 450 cm3 measured by MRI (or by CT for applicable subjects).
  • Total Symptom Score (TSS) ≥10 on the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0.
  • Peripheral blast count \<10%.
  • No MF-directed treatment for at least 2 weeks prior to initiation of NS-018, including JAK inhibitor, erythropoietic, thrombopoietic agent, or any use of for MF symptom or blood count management. Low dose corticosteroids \<10 mg/day prednisone or equivalent is allowed for non-MF purposes.

Exclusion criteria

Exclusion Criteria:

  • Active, uncontrolled systemic infection.
  • Any prior treatment with more than two JAK inhibitors.
  • Previous treatment with NS-018.
  • Subjects actively receiving a concurrent agent.
  • Subjects with any unresolved AE greater than Grade 1 other than hematological AEs from previous anticancer therapy.
  • Currently taking medication that is substantially metabolized by cytochrome P450 (CYP) 1A2 or (see Appendix 5) or taking medication known to be strong inhibitors or inducers of CYP3A4 (see Appendix 5).
  • Radiation therapy for splenomegaly within 6 months prior to study entry (screening).
  • History of splenectomy or planning to undergo splenectomy.
  • Subjects with a serious cardiac condition within the past 6 months such as uncontrolled arrhythmias, myocardial infarction, angina or heart disease
  • Subjects diagnosed with another within 2 years prior to an enrollment.
  • Subjects who have had surgery (other than placement of vascular access and bone marrow ) within 4 weeks of study entry (screening), or subjects with incomplete recovery from any prior surgical procedures.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    NS-018

    Self-administered NS-018 300 mg orally, twice daily, preferably at the same time each day in consecutive 4-week (28-day) cycles

    Drug: NS-018

  • Active comparator
    Best Available Therapy (BAT)

    Single agent per Investigator discretion or no therapy

    Drug: Best Available Therapy

Interventions

  • DrugNS-018

    Experimental

  • DrugBest Available Therapy

    Active Comparator

06

What researchers measure

Primary outcomes

  1. Change in Spleen Volume

    Proportion of subjects who achieve ≥35% reduction in spleen volume from baseline compared to Week 24 as measured by MRI (or by CT for applicable subjects)

    Time frame: baseline and week 24

  2. Change in Total Symptom Score (TSS)

    Proportion of subjects who achieve ≥50% reduction in total symptom score from baseline compared to Week 24 as measured by the MF-SAF v4.0

    Time frame: baseline and week 24

Secondary outcomes

  1. Change in Spleen Volume

    Proportion of subjects in NS-018 vs BAT arm who achieve ≥35% reduction in spleen volume from baseline at any time up to Week 24 as measured by MRI (or by CT for applicable subjects)

    Time frame: from baseline to anytime before or at week 24

  2. Comparison of Treatment-emergent AEs Between NS-018 and BAT

    Laboratory events graded by the NCI CTCAE v5.0 will be assessed in both arms, to compare the safety profile of NS-018 versus BAT.

    Time frame: from baseline to week 24

07

Results

Posted May 23, 2025
Limitations and caveats
The study was stopped early for business reasons. Therefore the efficacy outcomes were evaluated only in the limited number of patients enrolled.

Participant flow

Participant flow — Overall Study
MilestoneNS-018Best Available Therapy (BAT)
Started52
Completed00
Not completed52
Withdrew: Adverse event10
Withdrew: Study terminated by sponsor due to business reasons.22
Withdrew: Withdrawal by subject10
Withdrew: Other reasons10

Outcome measures

PrimaryChange in Spleen Volume

Proportion of subjects who achieve ≥35% reduction in spleen volume from baseline compared to Week 24 as measured by MRI (or by CT for applicable subjects)

Time frame:
baseline and week 24
Reported as:
Count of participants · Participants
Change in Spleen Volume
ParticipantsNS-018Best Available Therapy (BAT)
Change in Spleen Volume00
PrimaryChange in Total Symptom Score (TSS)

Proportion of subjects who achieve ≥50% reduction in total symptom score from baseline compared to Week 24 as measured by the MF-SAF v4.0

Time frame:
baseline and week 24
Reported as:
Count of participants · Participants
Change in Total Symptom Score (TSS)
ParticipantsNS-018Best Available Therapy (BAT)
Change in Total Symptom Score (TSS)01
SecondaryChange in Spleen Volume

Proportion of subjects in NS-018 vs BAT arm who achieve ≥35% reduction in spleen volume from baseline at any time up to Week 24 as measured by MRI (or by CT for applicable subjects)

Time frame:
from baseline to anytime before or at week 24
Reported as:
Count of participants · Participants
Change in Spleen Volume
ParticipantsNS-018Best Available Therapy (BAT)
Change in Spleen Volume10
SecondaryComparison of Treatment-emergent AEs Between NS-018 and BAT

Laboratory events graded by the NCI CTCAE v5.0 will be assessed in both arms, to compare the safety profile of NS-018 versus BAT.

Time frame:
from baseline to week 24
Reported as:
Count of participants · Participants
Comparison of Treatment-emergent AEs Between NS-018 and BAT
ParticipantsNS-018Best Available Therapy (BAT)
Comparison of Treatment-emergent AEs Between NS-018 and BAT52

Adverse events

Collected over from baseline to week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NS-0180/5 (0%)1/5 (20%)5/5 (100%)
Best Available Therapy (BAT)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventNS-018Best Available Therapy (BAT)
TracheobronchitisInfections and infestations1/50/2
Most frequent other events
Showing 10 of 45
Most frequent other events
EventNS-018Best Available Therapy (BAT)
AnaemiaBlood and lymphatic system disorders4/50/2
Conjunctival haemorrhageEye disorders1/51/2
Eyelid function disorderEye disorders0/51/2
Abdominal PainGastrointestinal disorders1/51/2
Lower respiratory tract infectionInfections and infestations0/51/2
HypokalaemiaMetabolism and nutrition disorders2/51/2
Neuropathy peripheralNervous system disorders0/51/2
Affective disorderPsychiatric disorders0/51/2
InsomniaPsychiatric disorders0/51/2
CoughRespiratory, thoracic and mediastinal disorders0/51/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NS-018Best Available Therapy (BAT)Total
<=18 years000
Between 18 and 65 years202
>=65 years325
Age, Continuous
Age, Continuous(Years)NS-018Best Available Therapy (BAT)Total
Mean65.0 ± 16.4870.5 ± 0.7166.6 ± 13.72
Sex: Female, Male
Sex: Female, Male(Participants)NS-018Best Available Therapy (BAT)Total
Female314
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NS-018Best Available Therapy (BAT)Total
Hispanic or Latino000
Not Hispanic or Latino527
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NS-018Best Available Therapy (BAT)Total
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American000
White224
More than one race000
Unknown or Not Reported000
08

Study locations

52 sites
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Houston Methodist Hospital
    Houston, Texas 77002, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Hamatologisch-onkologische Praxis Heinric/Bangerter Ausgsburg GbR
    Augsburg, 86150, Germany
  • Universitaetsklinikum Halle (Saale)
    Halle, 6120, Germany
  • Universitaetsklinikum Jena
    Jena, 07747, Germany
  • Universitätsmedizin Rostock
    Rostock, 18057, Germany
  • AO SS Antonio
    Alessandria, 15121, Italy
  • Azienda Ospedaliera SS. Antonio
    Alessandria, 15121, Italy
  • ASST Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • AOU "Policlinico - San Marco"
    Catania, 95123, Italy
  • ASST Fatebenefratelli Sacco
    Milano, 20121, Italy
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • AO di Rilievo Ntl A Cardarelli
    Naples, 80131, Italy
  • Azienda Ospedaliera di Rilievo Nazionale
    Naples, 80131, Italy
  • AO di Rilievo Nazionale
    Napoli, 80131, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
  • Istituto Nazionale Tumori Regina Elena IRCCS
    Roma, 00144, Italy
  • Azienda Ospedaliera Universitaria Policlinico Umberto I
    Roma, 00161, Italy
  • AO Uni Policlinico Umberto I
    Rome, 00161, Italy
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Banpo-dong, 164 KR, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Gyeongsang National University Hospital
    Jinju-si, 52727, Korea, Republic of
  • CHA Bundang Medical Center, CHA University
    Seongnam, 164 KR, Korea, Republic of
  • Soon Chun Hyang Central Medical Center
    Seoul, 4401, Korea, Republic of
  • Hospital Raja Permaisuri Bainun
    Ipoh, Perak 30450, Malaysia
  • Hospital Ampang
    Ampang, 68000, Malaysia
  • Hospital Sultanah Aminah
    Johor Bahru, 80100, Malaysia
  • Hospital Raja Perempuan Zainab II
    Kota Bahru, 15586, Malaysia
  • Hospital Queen Elizabeth
    Kota Kinabalu, 88586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Sunway Medical Centre
    Petaling Jaya, Malaysia
  • Hospital Pulau Pinang
    Pulau Pinang, 10990, Malaysia
  • Szpital Uniwersytecki nr 2 im. dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
  • Dolnośląskie Centrum Onkologii we Wrocławiu, Oddział Hematologiczny
    Wrocław, 53-413 ,, Poland
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Songklanagarind Hospital
    Songkla, 90110, Thailand
  • Istanbul Medipol University
    Bagcilar, Istanbul 34200, Turkey
  • Ege Universitesi Tip Fak,
    İzmir, Turkey
  • Namik Kemal University Medicine School
    Tekirdağ, 59100, Turkey
  • Karadeniz Teknik Universitesi Tip Fak,
    Trabzon, 61100, Turkey
  • Royal United Hospitals - Bath
    Bath, England BA1 3NG, United Kingdom
  • Guys Hospital
    London, England SE1 9RT, United Kingdom
  • University College London Hospitals
    London, England WC1E 6HX, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, England M20 4BX, United Kingdom
  • Derriford Hospital
    Plymouth, England PL6 8DH, United Kingdom
  • Sandwell & West Birmingham Hospital
    West Bromwich, England B71 4HJ, United Kingdom
  • Western General Hospital
    Edinburgh, Scotland EH2XU 4, United Kingdom
  • Western General Hospital
    Edinburgh, Scotland EH4 2XU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Submission to the FDA

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in May 2024, 15 months.

Results were first posted in May 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 22, 2021
StartActual
Jan 31, 2023
Primary completionActual
May 16, 2024
CompletionActual
May 16, 2024
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04854096
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Jan 31, 2023
Primary completion
May 16, 2024
Completion
May 16, 2024
Results posted
May 23, 2025
Last update
May 23, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion